Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | PTGFR | P43088 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7835398 | 1.00 | TACR1 (0.38) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL6052769 | 1.00 | TACR1 (0.38) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL2675548 | 1.00 | TACR1 (0.38) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL3141190 | 1.00 | TACR1 (0.38) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL6053005 | 0.93 | TACR1 (0.40) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL6494918 | 0.93 | TACR1 (0.40) | TACR1SIRT1FUCA1SLC15A1AGTR2 | |
| SCHEMBL6053036 | 0.83 | TACR1 (0.48) | TACR1SIRT1GAADPP4ACE | |
| SCHEMBL7531133 | 0.81 | TACR1 (0.44) | TACR1DPP4ACE | |
| SCHEMBL6052770 | 0.80 | FUCA1 (0.40) | TACR1SIRT1FUCA1GBA1GAA | |
| SCHEMBL6052771 | 0.80 | FUCA1 (0.40) | TACR1SIRT1FUCA1GBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | TACR1 1639/4885SIRT1 802/4885FUCA1 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.